Xtacy Therapeutics Corp. Stock Deutsche Boerse AG
Equities
TT5
CA98423G1072
Investment Management & Fund Operators
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 EUR | +23.08% | +23.08% | +28.00% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 2.46M 2.3M |
---|---|---|---|---|---|
Net income 2022 | -1M -935K | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net Debt 2022 | 25.37K 23.71K | Net Debt 2023 | 16.7K 15.61K | EV / Sales 2023 | - |
P/E ratio 2022 |
-3.97
x | P/E ratio 2023 |
-4.19
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.2% |
1 day | +23.08% | ||
1 week | +23.08% | ||
1 month | +23.08% | ||
3 months | -56.76% | ||
6 months | +60.00% | ||
Current year | +28.00% |
Managers | Title | Age | Since |
---|---|---|---|
Meris Kott
CEO | Chief Executive Officer | - | 17-11-29 |
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 19-04-09 |
Monita Faris
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 19-04-09 |
Meris Kott
CEO | Chief Executive Officer | - | 17-11-29 |
Ashleigh Vogstad
BRD | Director/Board Member | - | 19-10-29 |
Date | Price | Change |
---|---|---|
24-05-02 | 0.016 | +23.08% |
24-04-30 | 0.013 | -18.75% |
24-04-29 | 0.016 | 0.00% |
24-04-26 | 0.016 | -17.95% |
24-04-25 | 0.0195 | +18.18% |
Delayed Quote Deutsche Boerse AG, May 02, 2024 at 02:31 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-7.42% | 112B | |
-6.74% | 84.71B | |
+6.06% | 62.03B | |
+16.30% | 61.32B | |
+8.47% | 42.22B | |
+8.85% | 41.18B | |
+17.72% | 34.26B | |
+2.42% | 24.63B | |
-5.62% | 22.04B |
- Stock Market
- Equities
- XTCY Stock
- TT5 Stock